- Report
- October 2021
- 288 Pages
Global
From €3311EUR$3,600USD£2,821GBP
- Report
- August 2025
- 150 Pages
Global
From €2907EUR$3,160USD£2,476GBP
€3633EUR$3,950USD£3,095GBP
- Report
- July 2025
- 155 Pages
Global
From €4277EUR$4,650USD£3,644GBP
- Report
- September 2022
- 232 Pages
Global
From €3219EUR$3,500USD£2,743GBP
- Report
- August 2022
- 222 Pages
Global
From €3219EUR$3,500USD£2,743GBP
- Report
- February 2024
- 88 Pages
Global
From €3500EUR$4,076USD£3,086GBP
The Immune Disorders Drugs market includes drugs used to treat Inflammatory Bowel Disease (IBD). IBD is a chronic condition that causes inflammation of the digestive tract, leading to abdominal pain, diarrhea, and other symptoms. IBD drugs are used to reduce inflammation and improve symptoms. These drugs include corticosteroids, immunomodulators, biologics, and other medications. Corticosteroids are used to reduce inflammation and suppress the immune system, while immunomodulators are used to modify the immune system's response to inflammation. Biologics are used to target specific molecules involved in the inflammatory process.
Some companies in the IBD drug market include AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Janssen, Merck, Pfizer, and Takeda. Show Less Read more